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Membrane type 1 metalloprotease (MT1-MMP) is
a membrane-anchored, zinc-dependent protease.
MT1-MMP is an important mediator of cell migration
and invasion, and overexpression of this enzyme has
been correlatedwith themalignancy of various tumor
types. Therefore, modulators of MT1-MMP activity
are proposed to possess therapeutic potential in
numerous invasive diseases. Here we report the inhi-
bition mode of MT1-MMP by LEM-2/15 antibody,
which targets a surface epitope of MT1-MMP. Spe-
cifically, the crystal structures of Fab LEM-2/15 in
complex with theMT1-MMP surface antigen suggest
that conformational swiveling of the enzyme surface
loop is required for effective binding and consequent
inhibition of MT1-MMP activity on the cell mem-
brane. This inhibition mechanism appears to be
effective in controlling active MT1-MMP in endothe-
lial cells and at the leading edge of migratory cancer
cells.
INTRODUCTION
Proteases are a major class of enzymes involved in many phys-
iological processes, such as extracellular matrix (ECM) remodel-
ing, DNA replication and transcription, cell proliferation and
differentiation, and angiogenesis (Lo´pez-Otı´n and Matrisian,
2007a). Proteases were first considered as protein-degrading
enzymes. However, over the years, it has been realized that
they also play an important role as initiators of signaling cas-
cades, in which proteases have distinct and specific roles in
producing bioactive products (Liu et al., 2000; Lo´pez-Otı´n and
Overall, 2002; McQuibban et al., 2000; Wilson et al., 1999).
Imbalanced protease activity is often associated with patholog-
ical states such as inflammation, cancer, and infectious diseases
(Lo´pez-Otı´n and Matrisian, 2007a; Turk, 2006a), making them
highly important drug targets. For instance, overexpression of
proteases belonging to structurally homologous families, such
as cathepsin (Kawasaki et al., 2002; Koblinski et al., 2000), serine104 Structure 23, 104–115, January 6, 2015 ª2015 Elsevier Ltd All rigproteases (DeClerck and Imren, 1994), and matrix metalloprotei-
nases (Choi et al., 2012), are associated with various clinical
conditions.
MT1-MMP (membrane type I matrix metalloproteinase, MMP-
14) belongs to a large family of zinc-dependent matrix met-
alloproteases (MMPs) consisting of more than 23 structurally
homologousmembers as well asmore than 50 related proteases
(Bode et al., 1993). Beyond their key roles in ECM remodeling,
the MMPs are also implicated in the proteolytic processing of
other proteins, adhesion molecules, growth factors, cytokines,
and hormones (Brinckerhoff andMatrisian, 2002). Consequently,
these enzymes play key roles in many processes from cell pro-
liferation, differentiation, and communication to pathological
states associated with tumor metastasis, inflammation, tissue
degeneration, and cell death (Lo´pez-Otı´n and Matrisian, 2007a;
Nagase andWoessner, 1999; Overall, 2002). MT1-MMP belongs
to a subset of six membrane-tethered MMPs (MT1-MMP
throughMT6-MMP). MT1-MMP is involved inmany cellular func-
tions, including regulation of cell migration, invasion, angiogen-
esis, and induction of intracellular signaling pathways, and in
the intracellular traffic of proteinases (Jiang et al., 2001; Lehti
et al., 2000; Nakahara et al., 1997; Roghi et al., 2010; Rozanov
et al., 2002; Seiki, 2003; Uekita et al., 2001; Wang et al., 2004).
Its substrates include collagen types I, II, and III; gelatin; laminin;
fibronectin; vitronectin; aggrecan; fibrin; and lumican (Itoh et al.,
2006). In addition to ECM degradation, MT1-MMP also activates
proMMP-2 and proMMP-13 by forming a complex of a homo-
dimer ofMT1-MMP together with a tissue inhibitor of metallopro-
teinase-2 (TIMP-2) molecule on the cell surface (Butler et al.,
1998; Kna¨uper et al., 1996; Strongin et al., 1995). In addition,
recent shotgun proteomics approaches have expanded the
MT1-MMP substrate repertoire and identified a combinatorial
proteolytic program driven by MT1-MMP during angiogenesis
(Koziol et al., 2012a, 2012b).
MMPs, and MT1-MMP in particular, are well established tar-
gets for pharmaceutical development because of their tissue
remodelingmechanismsand their regulatory roles in invasivedis-
eases (Genı´s et al., 2006;Morrison et al., 2009). Most of theMMP
inhibitors developed to date have been designed to target the
active site zinc ion (Cuniasse et al., 2005; Fisher and Mobashery,
2006; Rao, 2005). However, these inhibitors displayed poor
selectivity among theMMPs and other related enzymes because
of the high structural homology at the active site (Overall andhts reserved
Figure 1. LEM-2/15 Binding to MT1-MMP
(A) CAT-MT1-MMP represented as ribbons. The
catalytic and structural zinc ions are shown as blue
spheres of arbitrary radii. The first and the second
calcium ions are shown as green spheres. Strands
and helices are labeled with numbers and Greek
letters. The V-B loop is highlighted in yellow mesh.
(B) Binding curves for intact LEM-2/15 (7)
(KD = 0.39 ± 0.05 nM) and the Fab (B) (KD = 2.27 ±
0.12 nM) to CAT-MT1-MMP. Error bars repre-
sent SD of representative experiments done in
triplicate.
(C) ELISA assay for LEM-2/15 binding to different
catalytic domains of MMP family members: MT1-
MMP (black), MMP-7 (red), MMP-9 (blue), and
MMP-12 (green). Because the binding is highly
selective toward MT1-MMP and the antibody
does not bind the other MMPs tested, their sym-
bols in the plot overlap. Error bars represent SD of
representative experiments done in triplicate.
(D) SPR measurements of Fab LEM-2/15 binding
to immobilized CAT-MT1-MMP: 2 nM (black),
5 nM (red), 10 nM (blue), 15 nM (green), and 20 nM
(magenta) (kaapp = 2.76 3 105 M1 s1, kdapp =
6.39 3 104 s1 and KappD = 2.32 3 10
9 M).
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Structural Swiveling Inhibition by AntibodyLo´pez-Otı´n, 2002). Importantly, the failure of broad-range small-
molecule inhibitors targeting the conserved MMP catalytic zinc
sites revived the field’s interest in designing specific inhibitors
to control thepathophysiological activity of theseenzymes in vivo
(Deu et al., 2012; Sela-Passwell et al., 2010; Turk, 2006a).
Therefore, targeting specific exosites residing outside of the
conserved catalytic cleft has been suggested as an alternate
drug design approach to control the destructive activity of
MMPs in vivo (Sela-Passwell et al., 2010; Udi et al., 2013).
Monoclonal antibodies can serve as valuable reagents for spe-
cific targeting of exposed surface loops of proteases, and, there-
fore, can be tailored to target regulatory exosites. A set of three
inhibitory antibodies targeted toward MT1-MMP, designated
LEM (Ga´lvez et al., 2001a), was generated against two exposed
loops of MT1-MMP (residues 160–173 and 218–233) by immu-
nizing mice with these peptides. These antibodies inhibit the
catalytic activity of MT1-MMP and further demonstrate antian-
giogenic properties in cell-based assays (Ga´lvez et al., 2001a).
However, the mechanism by which these antibodies control the
enzymatic activity of MT1-MMP and how they achieve selectivity
against other MMP family members is not clear. Therefore, un-
derstanding the mechanisms of their allosteric control is crucial
to advance our knowledge regarding the selective and specific
control of the enzymatic activity of MMPs for drug design.
Here we provide a detailed analysis of the interaction between
MT1-MMP and the Fab fragment of the antibody LEM-2/15. This
antibody was generated against the V-B loop of MT1-MMP situ-
ated above the specificity loop that connects b sheet V and a he-
lix B (Figure 1A) and displays high sequence divergence among
MMPs and, specifically, among the MT-MMP subfamily (Figures
S1A and S1B available online). Kinetic and binding studies
confirmed that this antibody and its Fab fragment are highly se-Structure 23, 10lective potent MT1-MMP inhibitors. The Fab fragment maintains
the functional antibody properties in various biological assays,
including in situ collagen zymography and proMMP-2 activation,
together with the absent effect in MT1-MMP homodimerization.
Using X-ray crystallography, we determined the structure of the
free and bound Fab, suggesting conformational rearrangements
of the enzyme scaffold to enable binding to the Fab fragment as a
possible mechanism to control the enzymatic activity. Computa-
tional analyses further support our experimental observation,
pointing to a role for conformational flexibility as mediating the
function of this enzyme.
RESULTS
LEM-2/15 Is a Highly Selective Anti-MT1-MMP Antibody
with Nanomolar Affinity
The antibody LEM-2/15 was generated by immunizing mice
with a cyclic peptide possessing the sequence of the V-B loop,
residues 218–233, which displays a unique sequence diver-
gence within the MMP family members, as we have described
previously (Ga´lvez et al., 2001a). To characterize the interaction
between MT1-MMP and the antibody, we sequenced the anti-
body and generated a minimized antibody fragment, the Fab
fragment, for easier handling and overexpression (Experimental
Procedures and Supplemental Experimental Procedures). Note-
worthy is that minimizing the size of the antibody may also offer
an advantage in drug design. The Fab fragment was overex-
pressed in twoways: from the periplasmic space ofE. coli, allow-
ing simplified processing, enhanced biological activity, higher
stability, and proper folding of the target protein (Mergulha˜o
et al., 2005), and from the hybridoma clone culture supernatant
of LEM-2/15 and by purification on a protein A column, followed4–115, January 6, 2015 ª2015 Elsevier Ltd All rights reserved 105
Figure 2. Inhibition of MT1-MMP Catalytic
Activity by Fab LEM-2/15
(A) Dose-response curve for MT1-MMP inhibition
by Fab LEM-2/15 using the 6-mer substrate (IC50 =
45 ± 2.4 nM).
(B) Lineweaver-Burk plots for MT1-MMP inhibition
by Fab LEM-2/15 indicating noncompetitive inhi-
bition. The Fab LEM-2/15 concentrations used
were 0 nM (C), 250 nM (:), and 500 nM (-).
(C) CAT-MT1-MMP (10 nM) was incubated with
1 mg/ml of collagen type I from rat tail in the
absence or presence of 1 mM of Fab LEM-2/15 or
1 mMMarimastat, and samples were processed by
12% SDS-PAGE gel. Fab LEM-2/15 dramatically
decreased the degradation process both after 5 hr
(left lanes) and overnight (O.N., right lanes), similar
to Marimastat.
(D) CAT-MT1-MMP (10 nM) was incubated with
10 mg/ml of gelatin in the absence or presence of
1 mM of Fab LEM-2/15 or 1 mM Marimastat, and
samples were processed by 12% SDS-PAGE
gel. Fab LEM-2/15 dramatically decreased the
degradation process both after 5 hr (left lanes) and
overnight (right lanes), similar to Marimastat.
Structure
Structural Swiveling Inhibition by Antibodyby digestion with papain (Experimental Procedures) to produce
the Fab fragment. To evaluate the potency of the generated
Fab fragment toward MT1-MMP, we determined its binding
affinity using ELISA assays and surface plasmon resonance
(SPR). The affinity of the produced Fab fragments (recombinant
and Fab from hybridoma) was tested against the catalytic
domain of recombinant MT1-MMP (CAT-MT1-MMP) and com-
pared with the binding of the intact antibody. Figure 1B shows
the ELISA binding curves of both constructs, indicating that
the intact antibody and the minimized Fab fragment possess
comparable binding affinities at the nanomolar range, 0.4 and
2.3 nM, respectively. In addition, we further demonstrated that
both the intact antibody and the Fab fragment recognize CAT-
MT1-MMP and the catalytic hemopexin domain construct
(CAT-HPX) of MT1-MMP with high affinity without any steric hin-
drance of the hemopexin domain to LEM-2/15 (Figures S2A and
S2B). Because the catalytic domain of the MMPmembers share
high structural homology, we further investigated the selectivity
of the Fab fragment toward MT1-MMP over other MMP mem-
bers, including MMP-7, MMP-9, and MMP-12, using an ELISA
assay as well as an ELISA competition assay. Remarkably, in
both experiments, the Fab fragment was highly selective toward
MT1-MMP over the other MMPs tested (Figure 1C; Figure S2C).
This result is consistent with the sequence divergence of the V-B
loop among the MMPs used to immunize the mice to generate
the LEM-2/15 antibody.
To obtain information regarding the binding kinetics of the
MT1-MMP:Fabcomplex,weperformeda real-timeSPRanalysis.
Diluted solutions of Fab LEM-2/15 were injected over surface-
immobilized CAT-MT1-MMP as we monitored the progress of
the binding over time. The changes in the SPR resonance,
due to changes in mass as a result of binding, were measured
(Figure 1D). The SPR analysis revealed that the Fab fragment
binds CAT-MT1-MMP with a kinetic association (kaapp) of
2.76 3 105 M1 s1, a kinetic dissociation (kdapp) of 6.39 3106 Structure 23, 104–115, January 6, 2015 ª2015 Elsevier Ltd All rig104 s1, and a dissociation constant ðKappD Þ of 2.32 3 109 M.
In addition, the formation of the Fab:enzyme complex was
observed by size exclusion chromatography (Figure S3A). The
eluted complex was identified according to its elution volume to
have a molecular weight of 70 kDa, and its content was
confirmed by 12% SDS-PAGE gel (Figure S3B) to be composed
of the CAT-MT1-MMP and the Fab LEM-2/15. This experiment
further indicates the formation of a high-affinity complex in
solution.
Fab LEM-2/15 Inhibits the Catalytic Activity of
MT1-MMP In Vitro
The effect of the Fab fragment on the enzymatic activity of CAT-
MT1-MMP was tested using three substrates. We first per-
formed enzyme kinetic assays on a small, fluorogenic, six-amino
acid substrate according to a standard procedure (Knight et al.,
1992). The enzymatic activity of recombinant CAT-MT1-MMP
was measured in the presence of increasing concentrations of
Fab LEM-2/15. Figure 2A shows the dose-response curve for
CAT-MT1-MMP inhibition with a half-maximal inhibitory concen-
tration (IC50) value of 45 ± 2.4 nM, demonstrating the high
potency of this Fab fragment as an inhibitor of the enzymatic ac-
tivity. Further kinetic analyses were performed to determine the
type of inhibition achieved by the Fab fragment. For this purpose,
a series of enzymatic activity assays using different Fab fragment
concentrations were performed. The obtained Lineweaver-Burk
plots (Figure 2B) demonstrate that the inhibition profile shows
a noncompetitive inhibition pattern. This was also indicated by
the kinetic parameters derived from the Lineweaver-Burk plots
(Table 1), where the maximum velocity (Vmax) is reduced with
the increase of LEM-2/15 concentration, whereas the affinity to
the substrate (KM) remained unchanged. Therefore, Fab LEM-
2/15 does not compete with the binding of the small substrate
at the catalytic zinc ion. This result indicates that the Fab
LEM-2/15 modulates the catalytic activity by binding at thehts reserved
Table 1. The Kinetic Activity of MT1-MMP in the Presence of
LEM-2/15
[LEM-2/15] nM Vmax (RFU/s) KM (uM)
0 68.3 24.3
250 50.5 25.1
500 36.9 24.4
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hindering it. We further evaluated the effect of the Fab fragment
on the enzymatic degradation of two physiological substrates of
MT1-MMP, collagen type I and gelatin. CAT-MT1-MMP was
incubated in the presence of Fab LEM-2/15 and added to sam-
ples of collagen type I or gelatin. Marimastat, a broad-spectrum
inhibitor of MMPs that binds to the zinc ion, was used as a
positive control to compare the degradation pattern with a
known potent inhibitor (Coussens et al., 2002; Rasmussen and
McCann, 1997). The samples were analyzed by 12% SDS-
PAGE gel after 5 and 16 hr, both analyses showing that the
inhibitors prevented the degradation of the substrates into low-
molecular-weight products (Figures 2C and 2D). Importantly,
the inhibitory effect of Fab LEM-2/15 on naturally occurring sub-
strates reveals a pronounced effect, demonstrating its inhibitory
potency on physiological substrates.
Structural Comparison of the Free Fab and the
MT1-MMP:Fab Complex
To determine how LEM-2/15 inhibits the catalytic activity of
CAT-MT1-MMP, we characterized their interaction by protein
crystallography. We obtained crystal structures of the free Fab
fragment at 2.6 A˚ resolution, two crystal forms of the Fab frag-
ment in complex with a segment of the V-B loop (residues
215–227) that diffracted to 1.94 and 1.95 A˚, and another crystal
structure of the Fab fragment in complex with a segment of the
V-B loop (residues 218–228) (Figure 3A; Figure S4A). (Data
collection and crystallographic refinement statistics are available
in Table S1.) All three structures of the Fab fragment coincide
with the structure of the free Fab with a root-mean-square devi-
ation (rmsd) of 0.4 A˚ (Figure S4A). Moreover, the V-B loop
observed in the structures align with an rmsd of 0.05 A˚ for the
structures with the 215–227 segment and an rmsd of 0.5 A˚ for
the 215–227 and 218–228 segments. Figures S4B and S4C
show their structural alignment. The Fab fragment structure ex-
hibits a typical architecture of antibodies, with a binding site lined
by residues of the complementarity-determining regions (CDRs).
The CDRs are assigned to known canonical structure classes
according to Chothia et al. (1989) (Table 2). However, they
form a relatively narrow antigen binding site compared with other
antibodies targeted against macromolecules (Wilson and Stan-
field, 1994). The crystal structures of the complex reveal that
the bound peptide interacts with all six CDRs through various
types of interactions (Figures 3B and 3C; Table 3). The major in-
teractions occur within residues Trp221 through Arg224. The
side chain of Trp221 forms a hydrogen bond and p-p interac-
tions with the side chain of Tyr101 (CDR L3) in addition to p-p in-
teractions with the side chain of Phe105 (H3). The side chain of
Thr222 forms hydrogen bonds with Gly53 (H2). In addition, the
side chain of Arg224 forms a salt bridge with Glu39 (L1) and aStructure 23, 10cation-p interaction with Tyr101 (L3) (Figure 3C). These highly
energetic interactions rationalize the high-affinity interaction be-
tween CAT-MT1-MMP and the Fab fragment, and it points the
loop toward the conformation observed in the crystal structure.
Interestingly, the conformation of the C-terminal part of the
bound peptide deviates from its corresponding segment in the
crystal structure of CAT-MT1-MMP in complex with TIMP-1
(Grossman et al., 2010) and TIMP-2 (Fernandez-Catalan et al.,
1998) because of the interaction of the Trp221 side chain with
the Fab fragment binding pocket (Figures 3A–3C). Importantly,
the side chains of both Trp221 and Arg224, when MT1-MMP is
bound to TIMP, point toward the core of the enzyme, whereas,
in our structure, they point outside, toward the binding site of
the Fab fragment. Therefore, it is reasonable to assume that
the binding to the Fab fragment induces these conformational
changes. In addition, the Fab residues that interact with
Trp221 and Arg224 of the MT1-MMP in the structure adopt a
similar orientation in the free Fab structure (Figure S4A), which
further supports the assumption that the change in the orienta-
tion of Trp221 and Arg224 of the MT1-MMP is induced by bind-
ing to the Fab. The comparison between the bound fragment and
its corresponding epitope from the MT1-MMP:TIMP structure is
shown in Figures 4B and 4C and Table S2. The major changes of
the torsional angles clearly demonstrate that there is a change in
conformation of the C-terminal part of the bound MT1-MMP
fragment affecting both Ca and the side chains. Another signifi-
cant change observed in the structure is the distance between
the Ca of Trp221 and Arg224. In our structure, the calculated dis-
tance is 5.6 A˚, whereas, in the structure of MT1-MMP in complex
with TIMP-1, the distance is as twice as long, 10.7 A˚ (Figures 4B
and 4C). This effect may arise because of the conformational re-
striction imposed by immunizing with a cyclic peptide corre-
sponding to the sequence of residues 218–233 of MT1-MMP
(Ga´lvez et al., 2001a). Therefore, this immunization strategy re-
sulted in an inhibitory antibody that induces the conformational
change according to its target conformation. Taking these find-
ings together, we propose that the conformational swiveling
motion of the V-B loop is critical in mediating the interaction be-
tween the Fab fragment and the enzyme. The obtained crystal
structures demonstrate that binding of MT1-MMP to the inhibi-
tory Fab fragment is mediated by highly energetic interactions
and involves the conformational rearrangement of the enzyme
scaffold controlling the enzymatic activity.
To test the possibility of the swiveling mechanism and, specif-
ically, the existence of the observed V-B loop conformation
within the ensemble of the possible conformations accessible
to this loop in the context of the CAT- MT1-MMP in solution,
we performed targeted molecular dynamics (TMD) simulations.
The simulation started from the conformation of CAT-MT1-
MMP as observed in its TIMP-1 complex (Protein Data Bank
[PDB] ID code 3MA2; Grossman et al., 2010). The targeted
conformation of CAT-MT1-MMP was defined using the coordi-
nates of 3MA2 for all residues of the catalytic domain, with
the exception of residues 215–228, whose coordinates were
taken from that observed for the peptide in complex with the
LEM-2/15 Fab. The rmsd of the 215–228 atoms between
the starting and the targeted conformation was about 3.0 A˚.
During the TMD simulation this RMSD was gradually reduced
to about 0.5A˚ (Figure S5). The final TMD structure of free4–115, January 6, 2015 ª2015 Elsevier Ltd All rights reserved 107
Figure 3. Structural Analyses of the Fab
Fragment with Its Antigen
(A) Surface representation with the secondary
structure highlighted for the complex between the
V-B loop of MT1-MMP (yellow) and Fab LEM-2/15
(light chain in blue, heavy chain in purple).
(B) Secondary structure representation of a close
view of interactions of CDR loops of Fab LEM-2/15
with the V-B loop. Central residues involved in the
binding interactions are highlighted in red (Trp221
and Arg224).
(C) Stick representation of the CDR residues in-
teracting with the V-B loop fragment of MT1-MMP.
Shown are hydrogen bond (black dashed line),
cation-p (brown dashed line), and electrostatic
interactions (light gray dashed line) between
Trp221 and Asn225 (yellow) and the Fab CDRs
(light chain in blue, heavy chain in purple).
(D) The V-B loop contact region on Fab LEM-2/15
(heavy chain contacts in orange, light chain con-
tacts in dark blue).
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in Figures 4A and 4D shows an excellent agreement of the pep-
tide 218–227 conformation with that observed in the Fab com-
plex. During the conformational transition between the starting
structure and the targeted one, no dramatic increase in total en-
ergy of the system or unrealistic conformational distortion of the
catalytic domain were observed. This suggests a possible low-
energy barrier between the two conformations (Figure S5). The
absence of a significant increase in total energy of the system
in conjunction with the preservation of the structure of CAT-
MT1-MMP during the transition driven by the artificial potential
Vrmsd argue for a possible population of this conformation of
the 215–227 peptide in the CAT-MT1-MMP in water solution.
To further estimate the stability of the final TMD conformation
obtained under rmsd restraints, we carried out a 10 ns unre-
strained molecular dynamics (MD) simulation in water solution.
We monitored the rmsd on the positions of the Ca atoms along
this trajectory compared with the final TMD conformation of
CAT-MT1-MMP. Two sets of atoms were considered. Set 1
corresponded to Ca atoms of residues 215–228, and set 2 cor-
responded to all Ca atoms of the CAT-MT1-MMP, with the
exception of the 215–233 region. The atoms of set 2 were used
to superimpose the structures of CAT-MT1-MMP of the different
frames analyzed by minimizing the rmsd on the position of their
coordinates with that of the starting MD structure (the final TMD
one). In this unrestrained MD simulation, the rmsds on the coor-
dinates of set 1 rapidly reached a value of about 5.0 A˚ compared
with the starting structure, whereas the rmsd corresponding to
set 2 remained below 2.0 A˚ (Figure S6). This observation strongly
suggests that the targeted TMD conformation of region 215–228108 Structure 23, 104–115, January 6, 2015 ª2015 Elsevier Ltd All rights reservedis not stable along the unrestrained MD
trajectory in the context of the CAT-
MT1-MMP at the free state. A similar
conclusion can be drawn from the anal-
ysis of the f and c dihedral angles and
the values of certain f-c angles obtained
(data not shown). Therefore, this confor-
mation is likely energetically less favor-able in the free enzyme and possibly only stabilized by the
interaction with the LEM-2/15. This mode of inhibition affects
the enzymatic activity of MT1-MMP in vitro by targeting hidden
regulatory exosites together with affecting the conformational
population in solution, which results in allosteric control of the
enzymatic function.
The conformational rearrangement suggested by the crystal
structure was confirmed by 1-anilinonaphthalene-8-sulfonic
acid (ANS) fluorescence assay. Typically, the fluorescence of
ANS is low in water solution and increases upon hydrophobic in-
teractions. This phenomenon makes ANS a sensitive probe to
detect conformational changes involving exposure of hydropho-
bic patches (Arighi et al., 1998; Raha et al., 1999). ANS emission
spectra (400–600 nm) were recorded in the presence of 5 mM
CAT-MT1-MMP, 5 mM Fab LEM-2/15, or the complex MT1-
MMP:Fab LEM-2/15. In the presence of each of the proteins,
ANS fluorescence did not change significantly, suggesting only
little binding of the probe to each of the proteins separately.
However, in the presence of the complex, ANS fluorescence
increased significantly (Figure 5A), indicating the exposure of a
hydrophobic surface area formed as a result of the conforma-
tional rearrangement induced by binding of Fab LEM-2/15. To
reveal the structural basis for the observed conformational
change, we compared the MT1-MMP TMD structure (containing
the swiveled V-B loop) with the known MT1-MMP crystal struc-
ture (PDB ID code 3MA2, in which the V-B loop adopts its
non-swiveled conformation). Remarkably, we observed a larger
hydrophobic surface area in the TMD structure, resulting, upon
swiveling of the V-B loop, in the calculated MT1-MMP structural
model corresponding to the binding of Fab LEM-2/15 (Figures
Table 3. Interactions Formed between the V-B Loop Residues
and the Fab Fragment
V-B Loop
Residue Numbera
Fab Fragment
Residue Number Type of Interaction CDR
Phe215 Ser32 H bond L1
Asp216 Tyr59 H bond H2
Ser217 – – –
Ala218 – – –
Glu219 His31 H bond L1
Pro220 Tyr59 hydrophobic H2
Trp221 Ala33 hydrophobic H1
Phe105 hydrophobic, p-p H3
Tyr101 hydrophobic,
H bond, p-p
L3
Thr222 Gly53 H bond H2
Glu99 H bond H3
Val223 Tyr32 hydrophobic H1
Tyr101 hydrophobic H3
Arg224 Gly102 H bond H3
Glu99 H bond H3
Gly96 H bond L3
Tyr37 cation-p L1
Tyr101 cation-p L3
Glu39 Ionic L1
Asn225 Tyr37 H bond L1
Glu226 – – –
Asp227 Asn35 H bond L1
Lys55 H bond, ionic L2
aThe underlined residues are the residues forming the major interactions
with the CDRs.
Table 2. Canonical Classes of Hypervariable Loops of Fab LEM-
2/15
CDR Residue Numbering Canonical Classa PDB ID Code
L1 24–39 4 1RMF
L2 55–61 1 1LMK
L3 94–102 1 1TET
H1 26–35 1 2FBJ
H2 50–58 3 1IGC
H3 99–107 – –
aStructural classification according to http://www.bioinf.org.uk/abs/
chothia.html.
Structure
Structural Swiveling Inhibition by Antibody5C and 5D). The side chains of Trp221 and Trp263 point outward
and contribute to a larger hydrophobic surface area, and a new
hydrophobic patch is formed by the side chains of Val223 and
Leu228. Accordingly, a significant change in the electrostatic
surface potential also occurs (Figures 5E and 5F), resulting in
partial loss of the negative electrostatic potential of the V-B
loop and formation of a negatively charged region in the cavity
formed by the V-B loop and a helix A. All of these changes
may affect the interaction of MT1-MMP with its physiological
substrates in vivo, which may require additional protein-protein
interaction on the surface of MT1-MMP. Aside from the changes
in hydrophobicity and electrostatic potential, Figures 5D and 5F
clearly demonstrate that the catalytic cleft adopts a narrower
conformation upon swiveling of the V-B loop. Finally, to identify
changes at the zinc active site, we performed X-ray absorption
spectroscopy (XAS). XAS evaluates the ligand environment of
the nearest coordination shell of the protein-bound metal ion
and, additionally, the metal electronic structure (up to 4 A˚).
This technique is ideal for obtaining accurate and precise solu-
tion structural data of metal ion complexes within the active sites
of metalloproteins (Frenkel et al., 2002; Sharma, 2012). The XAS
data of CAT-MT1-MMP in complex with Fab LEM-2/15 were
collected and analyzed (Figure 5B; Table S3). No changes in
spectral features or in the structural parameters of the catalytic
zinc histidine-nearest environment were detected upon binding
of Fab LEM-2/15 to CAT-MT1-MMP (Table S3; Grossman
et al., 2011; Udi et al., 2013). These results further indicate that
the structural changes of MT1-MMP occur at exosite regions,
and, therefore, it further supports the observed noncompetitive
mode of inhibition by Fab LEM-2/15.
Fab LEM-2/15 Affects the Catalytic Activity of
MT1-MMP in Cells, but It Does Not Impair Noncatalytic
Functions
To demonstrate the effect of the allosteric inhibition on cellular
activities of MT1-MMP, we performed functional assays where
MT1-MMP is known to play a key role in collagen degradation,
proMMP-2 activation, and homodimerization. Localization of
collagenolytic activity in cells is possible with the addition
a fluorescently quenched collagen type I (DQ-collagen). After
cleavage by MT1-MMP, fluorescent peptides are produced
and can by visualized and quantified (Bahar et al., 2007; Kay
et al., 1992). This functional assay was done using a human
fibrosarcoma cell line (HT1080) that overexpress MT1-MMP,
and the localization of collagenolytic activity was detected asStructure 23, 10green fluorescent areas because of DQ-collagen degradation.
Cells treated with Fab LEM-2/15 displayed reduced collagen
fluorescence, indicating a dose-dependent reduction in collage-
nolytic activity (Figures 6A and 6B), leading to a 75% decrease in
localized fluorescence in the presence of 5 mM Fab LEM-2/15.
Therefore, although LEM-2/15 does not bind at the active site,
it impairs the collagenase activity of the intact enzyme in the
native extracellular environment against a natural substrate.
The role of MT1-MMP is not restricted to degradation of the
ECMcomponents, and it was the first member of theMMP family
identified as physiologic activator of proMMP-2 (Browner et al.,
1995). This activation process is thought to be critical in cancer
invasion (Sato et al., 1994) and growth (Taniwaki et al., 2007)
because activated MMP-2 can degrade collagen type IV
whereas MT1-MMP does not. To test the effect of Fab LEM-2/
15 on the activation of proMMP-2 by MT1-MMP (Koshland and
Hamadani, 2002; Monod et al., 1965), human endothelial cells
were stimulated by wounding and the chemokine MCP-1 to
initiate the activation process in the presence of increasing con-
centrations of Fab LEM-2/15 or control immunoglobulin G (IgG).
Figure 6C demonstrates a moderate inhibitory effect of Fab
LEM-2/15 on proMMP-2 activation.
Finally, we tested the effect of Fab LEM-2/15 on the noncata-
lytic activity of MT1-MMP. MT1-MMP forms homodimers on the4–115, January 6, 2015 ª2015 Elsevier Ltd All rights reserved 109
Figure 4. TMD Demonstrating the Possibility of the V-B Loop to Accommodate the Conformation Observed in the Crystal Structure
(A) Superposition of the secondary structure representation of the TMD structure (blue) with the MT1-MMP structure (gray) (Grossman et al., 2010; PDB ID code
3MA2) and the V-B loop in our structure (yellow). The inset shows a close-up view of the V-B loop region.
(B) Ribbon representation of residues 216–227 and the distance between the Ca of Trp221 and Arg224 from PDB ID code 3MA2 (Grossman et al., 2010).
(C) Ribbon representation of residues 216–227 and the distance between the Ca of Trp221 and Arg224 from PDB ID code 4P3D.
(D) Ribbon representation of residues 216–227 and the distance between the Ca of Trp221 and Arg224 from the TMD structure.
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Structural Swiveling Inhibition by Antibodycell surface. This dimerization process was found to be crucial
for proMMP-2 activation and cleavage of collagen type I fibers
at the cell surface (Itoh et al., 2006). No significant effect on
homodimerization was detected in the presence of increasing
concentrations of Fab LEM-2/15 or control IgG in activated hu-
man endothelial cells (Figure 6D). Therefore, the Fab fragment
interacts specifically with the MT1-MMP expressed on the cell
surface and inhibits mostly its collagenase activity while not
interfering significantly with the activation of proMMP-2 and
the enzyme dimerization on the cell surface. This highly selective
inhibitory profile of LEM-2/15 may be relevant to other pathol-
ogies, such as infection, inflammation, and specific cancer pro-
cesses, in which activation of proMMP-2 is beneficial whereas
the collagenase activity by MT1-MMP is destructive. Overall,
we directly demonstrate that the Fab fragment controls the enzy-
matic activity of MT1-MMP on various substrates both in vitro
and in live cells.
DISCUSSION
In this work, we obtained and characterized a highly specific and
potent Fab fragment inhibitor of MT1-MMP. This Fab fragment is
selective towardMT1-MMP over other highly homologous family
members, and it inhibits the enzymatic activity in a noncompet-
itive manner, suggesting an allosteric mechanism of inhibition.
LEM-2/15 forms a high-affinity complex with MT1-MMP (in
the nanomolar range), and it inhibits the proteolytic activity of
MT1-MMP against a range of substrates. Structural comparison
between the free Fab fragment and in complex with a small
segment ofMT1-MMP suggests that the enzyme undergoesma-
jor conformational changes during binding to LEM-2/15. Specif-
ically, for the LEM-2/15 to bind Trp221 of MT1-MMP, the V-B
loop of the later has to ‘‘flip out’’ toward the antibody. This
change at the V-B loop leads to narrowing of the substrate bind-
ing cleft as the distance between the V-B loop and the S10 spec-110 Structure 23, 104–115, January 6, 2015 ª2015 Elsevier Ltd All rigificity loop is shortened from 7.8 A˚ between the Ca of Asn231and
the Ca of Trp263 in the structure of MT1-MMP:TIMP-1 (Gross-
man et al., 2010) to 4.3 A˚ in our TMD structure (Figure 4A). It
has been established that the V-B loop plays a role in the colla-
genolytic activity for MMP-1 (Chung et al., 2000), MMP-8 (Pel-
man et al., 2005), and MMP-12 (Bhaskaran et al., 2008; Chung
et al., 2000; Palmier et al., 2010) because it serves as a binding
site for collagen. Although such a role has not yet been investi-
gated for MT1-MMP, it is reasonable that the V-B loop serves
a similar role. In addition, in a previous study, we demonstrated
that this loop serves as a potential hidden regulatory site onMT1-
MMP, and nuclear magnetic resonance (NMR) analyses have
also demonstrated that this loop is highly flexible (Udi et al.,
2013). Based on the results discussed above, we would like to
offer three possible mechanisms for the inhibition: (1) Narrowing
the substrate binding cleft between the V-B loop and the S10 may
prevent substrate binding. (2) Constraining the flexibility of the
loop upon bindingmay alter the intrinsic dynamics of the enzyme
necessary for proper activity and substrate binding. (3) A combi-
nation of (1) and (2), where the combination of constrained
dynamics and conformational rearrangement of the V-B loop
during binding of the antibody constitute the basis of the allo-
steric nature of the antibody.
Our results demonstrate that LEM-2/15 inhibits mostly the
collagenase activity of MT1-MMP while not interfering signifi-
cantly with the activation of proMMP-2 and not affecting the
enzyme dimerization on the cell surface. Importantly, there are
specific stages in cancer progression in which activation of
proMMP-2 is beneficial, whereas uncontrolled MT1-MMP-medi-
ated collagen degradation is destructive (Genı´s et al., 2006;
McQuibban et al., 2000; Overall and Kleifeld, 2006). Therefore,
inhibiting only the collagenolytic activity, while not affecting other
important biological processes mediated by MT1-MMP, may be
superior over inhibitors blocking proMMP-2 activation in various
pathologies such as inflammation and infection diseases as wellhts reserved
Figure 5. Changes in the Surface Properties of MT1-MMP Induced by LEM-2/15 Binding
(A) ANS fluorescence assay. ANS (250 mM) was added to CAT-MT1-MMP (5 mM), Fab LEM-2/15 (5 mM), and a 1:1 complex. The samples were excited at 350 nm,
and fluorescence spectra (400–600 nm) were recorded. The fluorescence intensity was calculated as the area of the spectra at 400–600 nm (ANS, black; MT1-
MMP, red; Fab LEM-2/15, green; MT1-MMP:Fab LEM-2/15, blue). The inset shows emission spectra of the proteins in the presence of ANS (ANS, black; MT1-
MMP, red; Fab LEM-2/15, green; MT1-MMP:Fab LEM-2/15, blue). Error bars represent SD of representative experiments done in triplicate. a.u., arbitrary units.
(B) X-ray absorption spectra. Binding of Fab LEM-2/15 to CAT-MT1-MMP did not alter the zinc ion environment (CAT-MT1-MMP, black; CAT-MT1-MMP:Fab
LEM-2/15, red). No significant spectral changes were detected.
(C and D) Hydrophobic surface presentation of CAT-MT1-MMP. CAT-MT1-MMP is shown as a gray surface, and the hydrophobic side chains are presented in
green. (C) shows PDB ID code 3MA2, and (D) shows our TMD structure. The MT1-MMP binding site (V-B loop) to Fab LEM-2/15 is indicated.
(E and F) Surface electrostatic potential of CAT-MT1-MMP. Qualitative calculation of the surface electrostatic potential was done using the PyMOL molecular
graphics system (DeLano Scientific). Positive potential is shown in blue, whereas negative potential is shown in red. (E) shows PDB ID code 3MA2, and (F) shows
our TMD structure. The MT1-MMP binding site (V-B loop) to Fab LEM-2/15 is indicated.
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Figure 6. Effect of Fab LEM-2/15 on MT1-MMP Activity in Cells
(A) In situ zymography of collagen type I. HT1080 cells were grown on glass coverslips to adherence. Fab LEM-2/15 was added at 2 and 5 mM and left for 2 hr of
incubation at 37C prior to the addition of DQ-collagen type I. Cells were stained for MT1-MMP and nuclei (DAPI). Clearly, the increase in Fab LEM-2/15 con-
centration leads to a decrease in DQ-collagen fluorescence because of less degradation by MT1-MMP. CTRL, control.
(B) DQ collagen type I focal points per cell. The data from (A) were quantified, averaged, and plotted as focal points per cell, showing the reduction in
collagenolytic activity of MT1-MMPwith the increase in concentration of Fab LEM-2/15. Error bars represent SD of the average number of focal points per field of
view.
(C and D) Human endothelial cell monolayers were wounded and incubated with MCP-1 for 6 hr in addition to Fab LEM-2/15 or control IgG.
(C) ProMMP-2 activation was assessed by gelatin zymography of culture supernatants. Representative zymograms (top) and bar plots of MMP-2 fold change
activation compared with control cells (bottom) are shown (nR 6 independent experiments). Error bars represent SD of representative experiments.
(D) Plasmamembrane-enriched fractions were extractedwith Triton X-114, andMT1-MMP dimers were detected bywestern blot after a nonreducing SDS-PAGE
gel. Representative western blots (top) and bar plots of MT1-MMP fold change dimers compared with control cells (bottom) are shown (n = 4 independent
experiments). Error bars represent SD of representative experiments.
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Structural Swiveling Inhibition by Antibodyas specific states of cancer progression in which MMP-2 serves
as an antitarget (Overall and Kleifeld, 2006).
The design of future inhibitors possessing molecular interac-
tions with unique surface epitopes having a functional role shows
potential promise in improving drug selectivity. However, the
main challenge is the identification of such surface epitopes
and the design of appropriate antagonist molecules. Our struc-
tural study shows that the V-B loop epitope is an ideal candidate
for therapeutic design ofMT1-MMP inhibition because of its flex-
ibility and conformability, which can bemodulated by the binding
of function-blocking molecule such as an antibody. This work
demonstrates the importance of identifying surface epitopes in
the context of their enzymatic function to develop advanced in-
hibition strategies with improved selectivity.112 Structure 23, 104–115, January 6, 2015 ª2015 Elsevier Ltd All rigEXPERIMENTAL PROCEDURES
MT1-MMP Expression and Purification
CAT-MT1-MMP was overexpressed and purified as described previously (Udi
et al., 2013).
Antibody Purification
Hybridoma cells of LEM-2/15 were grown in DCCM (serum-free medium de-
signed for hybridoma cell growth and monoclonal antibody production, pur-
chased from Biological Industries). Cells were precipitated by centrifugation
at 193 3 g, and the supernatant was collected. The supernatant was dialyzed
against 20 mM phosphate buffer (pH 8). A 1 ml HiTrap protein A high-perfor-
mance column was equilibrated with 100 mM phosphate buffer (pH 8), and
the supernatant was loaded at 1 ml/min. The antibody was eluted with
100 mM citrate buffer (pH 6) and dialyzed against 50 mM Tris (pH 7.5) and
150 mM NaCl.hts reserved
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Papain was activated in 0.5 M Tris-HCl (pH 8), 10 mM EDTA, and 5mM dithio-
threitol for 15min at 37C. Active papain was added to a solution of intact LEM-
2/15 at a ratio of 1:1,000, and the digestion process was carried out for 3 h at
37C. The digestion reaction was terminated with the addition of 20mM iodoa-
cetamide in the dark at room temperature for 30 min. The Fab fragment was
isolated from the Fc by a protein A column, and the Fab fragment was
collected from the flowthrough and dialyzed against 50 mM Tris-HCl (pH
7.5) and 150 mM NaCl. The purity of the Fab fragment was estimated by
12% SDS-PAGE gel.
Fab Fragment Cloning, Expression, and Purification
The pGD2a phagemid expression vector containing the sequence of the Fab
fragment with a His tag at the C terminus was transformed into BL-21 bacteria
and grown on a lysogeny broth (LB)/ampicillin plate. Bacteria were grown in LB
medium containing 100 mg/ml ampicillin and 0.5% glucose in a shaker flask at
37C. Protein expression was induced with 0.5 mM isopropyl b-D-1-thiogalac-
topyranoside at optical density 600 nm = 0.6, and cell growth was continued
for a further 16 hr at 16C. Cells were harvested at 4,200 3 g for 15 min, and
the pellet was suspended in 75 ml ice-cold Tris-HCl (pH 7.4), 20% sucrose,
0.5 mg/ml lysozyme, 10–20 ml DNase I, and 2.5 mM MgCl2. Next, 75 ml of
ice-cold water with MgSO4 was added and left on ice for 10 min. The suspen-
sion was centrifuged for 40 min at 9,500 3 g. The supernatant was dialyzed
against 50mMTris-HCl and 150mMNaCl and purified on a nickel-nitrilotriace-
tic acid column.
MT1-MMP ELISA Binding Assay
A 96-well plate (Nunc) was coated with CAT-MMP at 5 mg/ml. After the plate
was coated, it was incubated with the Fab LEM-2/15 for 1 hr at 25C. The
bound Fab fragment was detected using a goat anti-Fab antibody followed
by peroxidase-conjugated antibody and bovine anti-goat antibody according
to standard procedures. The half-maximal effective concentration was calcu-
lated from a four-parametric sigmoidal curve-fitting analysis.
SPR Analysis
The affinity between Fab LEM-2/15 and CAT-MT1-MMP was measured with a
BIAcore 3000 instrument (Biacore). CAT-MT1-MMP was immobilized on a
CM5 sensor chip as described previously (Udi et al., 2013). Each binding
experiment was performed with a constant flow of 20 ml/min at 25C. Sixty mi-
croliters of Fab LEM-2/15 (1–20 nM) were injected over the surface for the as-
sociation phase. The surface was regenerated by the addition of 1 mM NaOH.
To estimate the increase in the response diffraction (response units [R.U.]) re-
sulting from nonspecific effects of the protein on the bulk refractive index, the
binding of the Fab fragment as a control with no immobilized protein was also
measured. This nonspecific signal was subtracted from the measured signal
for the interaction between CAT-MT1-MMP and Fab LEM-2/15 at all analyzed
concentrations. The data were fitted using a monophasic model for nonlinear
curve fitting, taking into account possible mass transport. Kinetic association
(ka) and dissociation (kd) rate constants were calculated using global spectrum
analysis as well as by fitting the individual association and dissociation phases
using the BIAevaluation 2.1 software package (Pharmacia).
MMP Enzymatic Assay
Kinetic Assays
The enzymatic activity of the CAT-MT1-MMP in the presence of Fab LEM-2/15
was measured at 37C by monitoring the hydrolysis of the fluorogenic peptide
Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 at lex = 340 nm and lem = 390 nm as
described previously (Knight et al., 1992). A range of different concentrations
of Fab LEM-2/15 (0–5,000 nM) were incubated with 10 nM of CAT-MT1-
MMP in 50 mM Tris-HCl buffer (pH 7.5 at 37C), 100 mM NaCl, 5 mM CaCl2,
and 0.05% Brij-35 for 2 hr at 37C. The enzymatic reaction was initiated by
addition of the fluorogenic peptide to a final concentration of 10 mM. Fluores-
cence was recorded immediately and continuously for 30 min. Initial reaction
rates were measured, and the inhibition constant was evaluated by fitting the
data to the equation
vi
v0
%=
1
1+ ½I
IC50
3 100;Structure 23, 10where vi is initial velocity in the presence of the inhibitor, v0 is the initial velocity
in the absence of inhibitor, and I is the inhibitor concentration.
To determine the type of inhibition, the initial velocity of CAT-MT1-MMPwas
measured as a function of substrate concentration (0–30 mM) at several fixed
concentrations of the Fab LEM-2/15 (between 0–500 nM). The values of
apparent KM and Vmax were derived by linearization according to the Linewea-
ver-Burk equation:
1
V
=
KM
Vmax
3
1
½S+
1
Vmax
:
SDS-PAGE Gel Activity Assay
CAT-MT1-MMP (10 nM) was incubated at 37C for 1 hr in the presence of 1 mM
Fab LEM-2/15 and Marimastat and in their absence. After incubation, 1 mg/ml
gelatin (porcine skin, Sigma) or rat tail collagen type I (Sigma) was added and
left at 37C. Samples were taken after 5 and 16 hr. The reaction was quenched
with 5 ml 43 sample buffer. Next, the samples were analyzed by 12% SDS-
PAGE gel.
Cell-Based Assays
In Situ Collagen Type I Zymography
HT1080 cells were cultured on glass coverslips in 24-well tissue culture plates
with 300 ml Dulbecco’s modified Eagle’s medium. After the cells adhered, Fab
LEM-2/15 was added for 2 hr of incubation at 37C prior to substrate addition.
1 mg/ml DQ collagen type I (Molecular Probes) was diluted to 40 mg/ml with
50 mM Tris (pH 7.5), 100 mM NaCl, 5 mM CaCl2, and 0.2 mM sodium azide.
Three hundred microliters of the diluted substrate were added, and the reac-
tion was carried out overnight at 37C. The next day, cells were washed with
PBS and fixed with 4% paraformaldehyde.
For immunostaining, cells were permeabilized with 0.5% saponin in PBS for
10 min and washed twice in PBS, and blocked with 1% BSA in PBS for 1 hr,
and then anti-mmp14 rabbit (Abcam, catalog no. ab 51074, 1:100 dilution)
was added to the blocking solution for 1 hr. Cells were washed twice in
PBS, and a secondary antibody, donkey anti-rabbit (Jackson ImmunoRe-
search Laboratories, catalog no. 711-605-152, 1:200 dilution) was added to
the blocking solution for 1 hr. Cells were washed with PBS, and DAPI was
added at 2 mg/ml for 10 min. Cells were washed in PBS, dried, mounted with
Elvanol, and dried overnight at room temperature. Samples were imaged using
a Nikon 80i Eclipse microscope.
Zymography and Western Blot in Human Endothelial Cells
Human umbilical vein endothelial cells (Lonza) were grown to confluence on
gelatin and starved in serum-freemedium (HE-SFM, Gibco) for 20 hr. Endothe-
lial cell monolayers were then scraped with a ‘‘tip’’ and incubated with 2 nM
MCP-1 in the same medium for 6 hr in the presence or absence of Fab
LEM-2/15 or complete antibody. Supernatants were collected and analyzed
by gelatin zymography (Ga´lvez et al., 2001a). To test MT1-MMP dimer forma-
tion, endothelial cell membranes were extracted in the hydrophobic fraction of
1.5% Triton X-114 lysates and resolved on 10% SDS-PAGE gel under strict
nonreducing conditions (Gunasekaran et al., 2004). Quantification was done
with ImageJ software.
Protein Crystallography
See Supplemental Experimental Procedures for a detailed description of crys-
tallization conditions, structure determination, and refinement.
ANS Fluorescence Assay
ANS was dissolved in water and filtered. ANS was added (250 mM) to 5 mM
CAT-MT1-MMP, Fab LEM, and the complex CAT-MT1-MMP:Fab LEM-2/15.
ANS was excited at 350 nm, and the emission spectra were recorded at
400–600nm.
XAS Measurement and Analyses
CAT-MT1-MMP (200 mM final concentration) was incubated at 37C for 2 hr
with Fab LEM-2/15 at 1:1 molar ratios. The sample was loaded, measured,
and analyzed as described previously (Solomon et al., 2007; Udi et al., 2013).
MD Simulations and TMD
See Supplemental Experimental Procedures for detailed descriptions of MD
simulations and TMD calculations.4–115, January 6, 2015 ª2015 Elsevier Ltd All rights reserved 113
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